AHA yesterday sent a letter to the Department of Justice’s Antitrust Division expressing its serious concern with the adequacy of any remedy to resolve the anticompetitive impact of UnitedHealth Group’s acquisition of Change Healthcare. UHG in January announced its intent to combine its Optum health services subsidiary with Change Healthcare, a health care technology firm, to provide software and data analytics, technology-enabled services and research, advisory and revenue cycle management services.

At the time, AHA argued that the deal would distort “decisions about patient care and claims processing and denials to the detriment of consumers and health care providers and further increase UHG’s already massive market power.” In the newest letter AHA reiterated that “it is highly unlikely that any remedy will preserve the substantial level of competition between the parties that will be lost if the transaction is completed.”

Related News Articles

Perspective
Five weeks from now, Congress will begin a five-week district and state work period, with House and Senate members leaving Washington, D.C. from early August…
Headline
The House Energy and Commerce Committee June 12 passed AHA-supported legislation during a markup of bills that passed the Health Subcommittee in May. The…
Headline
The AHA praised House and Senate leaders in letters June 12 for reintroducing the Improving Seniors’ Timely Access to Care Act, bipartisan legislation that…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Headline
The House Energy and Commerce Oversight and Investigations subcommittee June 4 hosted a hearing to discuss oversight of the 340B Drug Pricing Program. AHA sent…
Headline
A coalition of 230 national associations, including the AHA, submitted a letter the week of May 20 to the Federal Trade Commission requesting a stay on the…